<p>PROCEPT BioRobotics（纳斯达克：PRCT - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员将评级从 “卖出” 上调至 “持有”。</p>
<p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
<ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
<p>PRCT 已成为其他多份报告的主题。Oppenheimer 将 PROCEPT BioRobotics 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 9 月 2 日的报告中设定了 60.00 美元的股票目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 PROCEPT BioRobotics 股票的 “卖出（e+）” 评级。TD Cowen 将 PROCEPT BioRobotics 的目标价从 85.00 美元下调至 50.00 美元，并在 11 月 5 日的研究报告中对该公司设定了 “买入” 评级。Piper Sandler 在 11 月 5 日的研究报告中重申了 “增持” 评级，并将 PROCEPT BioRobotics 的目标价设定为 50.00 美元（低于 55.00 美元）。最后，Leerink Partners 在 11 月 5 日的研究报告中重新发布了 “跑赢大盘” 评级，并对 PROCEPT BioRobotics 的股票设定了 55.00 美元的目标价。九位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，PROCEPT BioRobotics 目前的平均评级为 “适度买入”，共识目标价为 57.89 美元。</p>
<p><strong>获取我们最新的 PRCT 股票报告</strong></p>
<h2>PROCEPT BioRobotics 股票表现</h2>
<ul>
<li>为什么 Intuitive Surgical 股票在医疗领域占据主导地位</li>
</ul>
<p>PRCT 股票在周五开盘价为 35.86 美元。该公司的市值为 20 亿美元，市盈率为-23.44，贝塔值为 0.99。PROCEPT BioRobotics 的十二个月低点为 27.80 美元，十二个月高点为 97.49 美元。该公司的债务与股本比率为 0.14，速动比率为 7.20，流动比率为 8.44。该公司的 50 日移动平均价格为 33.03 美元，200 日移动平均价格为 44.36 美元。</p>
<p>PROCEPT BioRobotics（纳斯达克：PRCT - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告季度每股收益（EPS）为（0.38 美元），超出分析师共识预期的（0.41 美元）0.03 美元。该季度的营业收入为 8333 万美元，而分析师预期为 8078 万美元。PROCEPT BioRobotics 的净利润率为-28.20%，股本回报率为-21.72%。该公司的季度收入同比增长 42.6%。去年同期，该公司的每股收益为（0.40 美元）。分析师平均预测，PROCEPT BioRobotics 在当前财政年度将发布-1.75 美元的每股收益。</p>
<h2>对 PROCEPT BioRobotics 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对 PRCT 的持仓进行了调整。JTC Employer Solutions Trustee Ltd 在第三季度购买了 PROCEPT BioRobotics 的新股份，价值 30,000 美元。BI Asset Management Fondsmaeglerselskab A S 在第一季度购买了 PROCEPT BioRobotics 的新股份，价值约 40,000 美元。Vega Investment Solutions 在第二季度将其在 PROCEPT BioRobotics 的股份增加了 52.0%。Vega Investment Solutions 现在拥有 775 股该公司的股票，价值 45,000 美元，此前在上个季度购买了 265 股。US Bancorp DE 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 175.7%。US Bancorp DE 现在拥有 1693 股该公司的股票，价值 60,000 美元，此前在此期间购买了 1079 股。最后，AlphaQuest LLC 在第二季度将其在 PROCEPT BioRobotics 的股份增加了 1262.5%。AlphaQuest LLC 现在拥有 1090 股该公司的股票，价值 63,000 美元，此前在上个季度购买了 1010 股。89.46% 的股票由机构投资者持有。</p>
<h2>PROCEPT BioRobotics 公司简介</h2>
<p>（获取免费报告）</p>
<p>PROCEPT BioRobotics Corporation 是一家外科机器人公司，专注于在美国和国际上开发变革性泌尿学解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种用于微创泌尿外科手术的图像引导外科机器人系统，重点治疗良性前列腺增生（BPH）。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 PROCEPT BioRobotics</li>
<li>想在下跌趋势中获利？下跌趋势的解释。</li>
<li>Rocket Lab 的大反弹？分析师建议这次下跌是个机会</li>
<li>复利及其在投资中的重要性</li>
<li>Meta 的 AI 时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>即将到来的 IPO 股票锁定期，解释</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
<p>在你考虑 PROCEPT BioRobotics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PROCEPT BioRobotics 并不在名单上。</p>
<p>虽然 PROCEPT BioRobotics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRCT

<p>华尔街禅将 PROCEPT BioRobotics（NASDAQ:PRCT）的评级从 “卖出” 上调至 “持有”。其他分析师的观点各异，有些设定的目标价在 50 美元到 60 美元之间。该公司报告的季度收益超出预期，收入同比增长 42.6%。机构投资者持有该公司 89.46% 的股份。PROCEPT BioRobotics 专注于泌尿外科手术机器人，特别是治疗良性前列腺增生（BPH）</p>

<p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（纳斯达克：PRCT - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员将评级从 “卖出” 上调至 “持有”。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
</div><p>PRCT has been the topic of a number of other reports. Oppenheimer upgraded PROCEPT BioRobotics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $60.00 price target on the stock in a report on Tuesday, September 2nd. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of PROCEPT BioRobotics in a research note on Wednesday, October 8th. TD Cowen reduced their price target on PROCEPT BioRobotics from $85.00 to $50.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday, November 5th. Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $50.00 price target (down from $55.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Finally, Leerink Partners reissued an &#34;outperform&#34; rating and issued a $55.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $57.89.</p>
<div class="lb-trans"><p>PRCT 已成为其他多份报告的主题。Oppenheimer 将 PROCEPT BioRobotics 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 9 月 2 日的报告中设定了 60.00 美元的股票目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 PROCEPT BioRobotics 股票的 “卖出（e+）” 评级。TD Cowen 将 PROCEPT BioRobotics 的目标价从 85.00 美元下调至 50.00 美元，并在 11 月 5 日的研究报告中对该公司设定了 “买入” 评级。Piper Sandler 在 11 月 5 日的研究报告中重申了 “增持” 评级，并将 PROCEPT BioRobotics 的目标价设定为 50.00 美元（低于 55.00 美元）。最后，Leerink Partners 在 11 月 5 日的研究报告中重新发布了 “跑赢大盘” 评级，并对 PROCEPT BioRobotics 的股票设定了 55.00 美元的目标价。九位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，PROCEPT BioRobotics 目前的平均评级为 “适度买入”，共识目标价为 57.89 美元。</p>
</div><p><strong>Get Our Latest Stock Report on PRCT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 PRCT 股票报告</strong></p>
</div><h2>PROCEPT BioRobotics Stock Performance</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票表现</h2>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Intuitive Surgical 股票在医疗领域占据主导地位</li>
</ul>
</div><p>Shares of PRCT opened at $35.86 on Friday. The firm has a market cap of $2.00 billion, a P/E ratio of -23.44 and a beta of 0.99. PROCEPT BioRobotics has a twelve month low of $27.80 and a twelve month high of $97.49. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44. The firm's 50 day moving average price is $33.03 and its two-hundred day moving average price is $44.36.</p>
<div class="lb-trans"><p>PRCT 股票在周五开盘价为 35.86 美元。该公司的市值为 20 亿美元，市盈率为-23.44，贝塔值为 0.99。PROCEPT BioRobotics 的十二个月低点为 27.80 美元，十二个月高点为 97.49 美元。该公司的债务与股本比率为 0.14，速动比率为 7.20，流动比率为 8.44。该公司的 50 日移动平均价格为 33.03 美元，200 日移动平均价格为 44.36 美元。</p>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.03. The business had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The firm's quarterly revenue was up 42.6% on a year-over-year basis. During the same period last year, the business posted ($0.40) earnings per share. On average, analysts forecast that PROCEPT BioRobotics will post -1.75 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（纳斯达克：PRCT - 获取免费报告）最近在 11 月 4 日发布了季度财报。该公司报告季度每股收益（EPS）为（0.38 美元），超出分析师共识预期的（0.41 美元）0.03 美元。该季度的营业收入为 8333 万美元，而分析师预期为 8078 万美元。PROCEPT BioRobotics 的净利润率为-28.20%，股本回报率为-21.72%。该公司的季度收入同比增长 42.6%。去年同期，该公司的每股收益为（0.40 美元）。分析师平均预测，PROCEPT BioRobotics 在当前财政年度将发布-1.75 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>对 PROCEPT BioRobotics 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in PRCT. JTC Employer Solutions Trustee Ltd bought a new stake in PROCEPT BioRobotics during the third quarter worth $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of PROCEPT BioRobotics in the 1st quarter valued at about $40,000. Vega Investment Solutions increased its stake in shares of PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company's stock worth $45,000 after purchasing an additional 265 shares during the last quarter. US Bancorp DE raised its holdings in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company's stock valued at $60,000 after purchasing an additional 1,079 shares during the period. Finally, AlphaQuest LLC lifted its stake in PROCEPT BioRobotics by 1,262.5% in the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company's stock valued at $63,000 after purchasing an additional 1,010 shares during the last quarter. 89.46% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 PRCT 的持仓进行了调整。JTC Employer Solutions Trustee Ltd 在第三季度购买了 PROCEPT BioRobotics 的新股份，价值 30,000 美元。BI Asset Management Fondsmaeglerselskab A S 在第一季度购买了 PROCEPT BioRobotics 的新股份，价值约 40,000 美元。Vega Investment Solutions 在第二季度将其在 PROCEPT BioRobotics 的股份增加了 52.0%。Vega Investment Solutions 现在拥有 775 股该公司的股票，价值 45,000 美元，此前在上个季度购买了 265 股。US Bancorp DE 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 175.7%。US Bancorp DE 现在拥有 1693 股该公司的股票，价值 60,000 美元，此前在此期间购买了 1079 股。最后，AlphaQuest LLC 在第二季度将其在 PROCEPT BioRobotics 的股份增加了 1262.5%。AlphaQuest LLC 现在拥有 1090 股该公司的股票，价值 63,000 美元，此前在上个季度购买了 1010 股。89.46% 的股票由机构投资者持有。</p>
</div><h2>PROCEPT BioRobotics Company Profile</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p>
<div class="lb-trans"><p>PROCEPT BioRobotics Corporation 是一家外科机器人公司，专注于在美国和国际上开发变革性泌尿学解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种用于微创泌尿外科手术的图像引导外科机器人系统，重点治疗良性前列腺增生（BPH）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 PROCEPT BioRobotics</li>
<li>想在下跌趋势中获利？下跌趋势的解释。</li>
<li>Rocket Lab 的大反弹？分析师建议这次下跌是个机会</li>
<li>复利及其在投资中的重要性</li>
<li>Meta 的 AI 时刻？新 SAM 3 模型让华尔街变得乐观</li>
<li>即将到来的 IPO 股票锁定期，解释</li>
<li>Snowflake 股票：聪明投资者正在购买的下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=PRCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PROCEPT BioRobotics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 PROCEPT BioRobotics 并不在名单上。</p>
</div><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PROCEPT BioRobotics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

华尔街禅将 PROCEPT BioRobotics（NASDAQ:PRCT）的评级上调至持有